2
|
Ma W, Jia K, Cheng H, Xu H, Li Z, Zhang H, Xie H, Sun H, Yi L, Chen Z, Duan S, Sano M, Fukuda K, Lu L, Gao F, Zhang R, Yan X. Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via Histone Lactylation. Circ Res 2024; 134:1427-1447. [PMID: 38629274 DOI: 10.1161/circresaha.123.323699] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 04/02/2024] [Indexed: 05/25/2024]
Abstract
BACKGROUND Medial arterial calcification is a chronic systemic vascular disorder distinct from atherosclerosis and is commonly observed in patients with chronic kidney disease, diabetes, and aging individuals. We previously showed that NR4A3 (nuclear receptor subfamily 4 group A member 3), an orphan nuclear receptor, is a key regulator in apo (apolipoprotein) A-IV-induced atherosclerosis progression; however, its role in vascular calcification is poorly understood. METHODS We generated NR4A3-/- mice and 2 different types of medial arterial calcification models to investigate the biological roles of NR4A3 in vascular calcification. RNA-seq was performed to determine the transcriptional profile of NR4A3-/- vascular smooth muscle cells under β-glycerophosphate treatment. We integrated Cleavage Under Targets and Tagmentation analysis and RNA-seq data to further investigate the gene regulatory mechanisms of NR4A3 in arterial calcification and target genes regulated by histone lactylation. RESULTS NR4A3 expression was upregulated in calcified aortic tissues from chronic kidney disease mice, 1,25(OH)2VitD3 overload-induced mice, and human calcified aorta. NR4A3 deficiency preserved the vascular smooth muscle cell contractile phenotype, inhibited osteoblast differentiation-related gene expression, and reduced calcium deposition in the vasculature. Further, NR4A3 deficiency lowered the glycolytic rate and lactate production during the calcification process and decreased histone lactylation. Mechanistic studies further showed that NR4A3 enhanced glycolysis activity by directly binding to the promoter regions of the 2 glycolysis genes ALDOA and PFKL and driving their transcriptional initiation. Furthermore, histone lactylation promoted medial calcification both in vivo and in vitro. NR4A3 deficiency inhibited the transcription activation and expression of Phospho1 (phosphatase orphan 1). Consistently, pharmacological inhibition of Phospho1 attenuated calcium deposition in NR4A3-overexpressed vascular smooth muscle cells, whereas overexpression of Phospho1 reversed the anticalcific effect of NR4A3 deficiency in vascular smooth muscle cells. CONCLUSIONS Taken together, our findings reveal that NR4A3-mediated histone lactylation is a novel metabolome-epigenome signaling cascade mechanism that participates in the pathogenesis of medial arterial calcification.
Collapse
MESH Headings
- Animals
- Vascular Calcification/metabolism
- Vascular Calcification/genetics
- Vascular Calcification/pathology
- Mice
- Mice, Knockout
- Humans
- Histones/metabolism
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Mice, Inbred C57BL
- Nuclear Receptor Subfamily 4, Group A, Member 3/metabolism
- Nuclear Receptor Subfamily 4, Group A, Member 3/genetics
- Male
- Myocytes, Smooth Muscle/metabolism
- Myocytes, Smooth Muscle/pathology
- Cells, Cultured
- DNA-Binding Proteins
- Nerve Tissue Proteins
- Receptors, Steroid
- Receptors, Thyroid Hormone
Collapse
Affiliation(s)
- Wenqi Ma
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Kangni Jia
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Haomai Cheng
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Hong Xu
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Zhigang Li
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Hang Zhang
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Hongyang Xie
- Institute of Cardiovascular Diseases (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Hang Sun
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Lei Yi
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Zhiyong Chen
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Shengzhong Duan
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
- Laboratory of Oral Microbiota and Systemic Diseases, Shanghai Ninth People's Hospital, College of Stomatology (S.D.), Shanghai Jiao Tong University School of Medicine, China
- Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital (S.D.), Shanghai Jiao Tong University School of Medicine, China
| | - Motoaki Sano
- Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (M.S., K.F.)
| | - Keiichi Fukuda
- Department of Cardiology, Keio University School of Medicine, Tokyo, Japan (M.S., K.F.)
| | - Lin Lu
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Fei Gao
- Beijing Anzhen Hospital, Capital Medical University, China (F.G.)
| | - Ruiyan Zhang
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| | - Xiaoxiang Yan
- Department of Cardiovascular Medicine, Ruijin Hospital (W.M., K.J., H.C., Z.L., H.Z., H.X., L.Z., Z.W., Y.C., H.S., L.Y., Z.C., L.L., R.Z., X.Y.), Shanghai Jiao Tong University School of Medicine, China
| |
Collapse
|
3
|
Li F, Si W, Xia L, Yin D, Wei T, Tao M, Cui X, Yang J, Hong T, Wei R. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. Mol Cancer 2024; 23:90. [PMID: 38711083 PMCID: PMC11071201 DOI: 10.1186/s12943-024-02008-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Accepted: 04/24/2024] [Indexed: 05/08/2024] Open
Abstract
BACKGROUND Metabolic reprogramming and epigenetic alterations contribute to the aggressiveness of pancreatic ductal adenocarcinoma (PDAC). Lactate-dependent histone modification is a new type of histone mark, which links glycolysis metabolite to the epigenetic process of lactylation. However, the role of histone lactylation in PDAC remains unclear. METHODS The level of histone lactylation in PDAC was identified by western blot and immunohistochemistry, and its relationship with the overall survival was evaluated using a Kaplan-Meier survival plot. The participation of histone lactylation in the growth and progression of PDAC was confirmed through inhibition of histone lactylation by glycolysis inhibitors or lactate dehydrogenase A (LDHA) knockdown both in vitro and in vivo. The potential writers and erasers of histone lactylation in PDAC were identified by western blot and functional experiments. The potential target genes of H3K18 lactylation (H3K18la) were screened by CUT&Tag and RNA-seq analyses. The candidate target genes TTK protein kinase (TTK) and BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) were validated through ChIP-qPCR, RT-qPCR and western blot analyses. Next, the effects of these two genes in PDAC were confirmed by knockdown or overexpression. The interaction between TTK and LDHA was identified by Co-IP assay. RESULTS Histone lactylation, especially H3K18la level was elevated in PDAC, and the high level of H3K18la was associated with poor prognosis. The suppression of glycolytic activity by different kinds of inhibitors or LDHA knockdown contributed to the anti-tumor effects of PDAC in vitro and in vivo. E1A binding protein p300 (P300) and histone deacetylase 2 were the potential writer and eraser of histone lactylation in PDAC cells, respectively. H3K18la was enriched at the promoters and activated the transcription of mitotic checkpoint regulators TTK and BUB1B. Interestingly, TTK and BUB1B could elevate the expression of P300 which in turn increased glycolysis. Moreover, TTK phosphorylated LDHA at tyrosine 239 (Y239) and activated LDHA, and subsequently upregulated lactate and H3K18la levels. CONCLUSIONS The glycolysis-H3K18la-TTK/BUB1B positive feedback loop exacerbates dysfunction in PDAC. These findings delivered a new exploration and significant inter-relationship between lactate metabolic reprogramming and epigenetic regulation, which might pave the way toward novel lactylation treatment strategies in PDAC therapy.
Collapse
Affiliation(s)
- Fei Li
- Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China
| | - Wenzhe Si
- Department of Laboratory Medicine, Peking University Third Hospital, Beijing, 100191, China
| | - Li Xia
- Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China
| | - Deshan Yin
- Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China
| | - Tianjiao Wei
- Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China
| | - Ming Tao
- Department of General Surgery, Peking University Third Hospital, Beijing, 100191, China
| | - Xiaona Cui
- Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China
| | - Jin Yang
- Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China
| | - Tianpei Hong
- Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.
| | - Rui Wei
- Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, 100191, China.
| |
Collapse
|
4
|
Zhang J, Lv W, Zhang G, Zeng M, Cao W, Su J, Cao K, Liu J. Nuclear Factor Erythroid 2 Related Factor 2 and Mitochondria Form a Mutually Regulating Circuit in the Prevention and Treatment of Metabolic Syndrome. Antioxid Redox Signal 2024. [PMID: 38183629 DOI: 10.1089/ars.2023.0339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2024]
Abstract
Significance: Metabolic syndrome (MetS) has become a major global public health problem and there is an urgent need to elucidate its pathogenesis and find more effective targets and modalities for intervention. Recent Advances: Oxidative stress and inflammation are two of the major causes of MetS-related symptoms such as insulin resistance and obesity. Nuclear factor erythroid 2 related factor 2 (Nrf2) is one of the important systems responding to oxidative stress and inflammation. As cells undergo stress, cysteines within Kelch-like ECH-associated protein 1 (Keap1) are oxidized or electrophilically modified, allowing Nrf2 to escape ubiquitination and be translocated from the cytoplasm to the nucleus, facilitating the initiation of the antioxidant transcriptional program. Meanwhile, a growing body of evidence points out a specific modulation of mitochondrial homeostasis by Nrf2. After nuclear translocation, Nrf2 activates downstream genes involved in various aspects of mitochondrial homeostasis, including mitochondrial biogenesis and dynamics, mitophagy, aerobic respiration, and energy metabolism. In turn, mitochondria reciprocally activate Nrf2 by releasing reactive oxygen species and regulating antioxidant enzymes. Critical Issues: In this review, we first summarize the interactions between Nrf2 and mitochondria in the modulation of oxidative stress and inflammation to ameliorate MetS, then propose that Nrf2 and mitochondria form a mutually regulating circuit critical to maintaining homeostasis during MetS. Future Directions: Targeting the Nrf2-mitochondrial circuit may be a promising strategy to ameliorate MetS, such as obesity, diabetes, and cardiovascular diseases.
Collapse
Affiliation(s)
- Jiawei Zhang
- Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China
| | - Weiqiang Lv
- Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China
| | - Guanfei Zhang
- Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China
| | - Mengqi Zeng
- Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China
| | - Wenli Cao
- Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China
| | - Jiacan Su
- Department of Orthopedics Trauma, Shanghai Changhai Hospital, Naval Military Medical University, Shanghai, China
| | - Ke Cao
- Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China
| | - Jiankang Liu
- Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China
- School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China
| |
Collapse
|